- Smoking Lowers Breast Cancer Survival Rates
- Understanding the Link Between Phthlate Exposure and Breast Cancer Risk
- Young Women with Breast Cancer Have Unique Needs
- Texts Boost Breast Cancer Screening Numbers
- Promoting Effective Communication About Breast Cancer Overdiagnosis
- Patient Leaflets Don’t Affect Interest in Mammogram Screening
- Genetic Anomalies Linked to Breast Cancer in African American Families
- FDA Approves New Drug for Patients with Advanced Breast Cancer
- Women with Atypical Hyperplasia Have a Higher Risk of Breast Cancer
- Mastectomy Patients Most Satisfied with Breast Reconstruction Using Their Own Tissues
New Study May Lead to New Strategies for Treatment of Alzheimer’s
Tau protein is common in the central nervous system where it helps to stabilize microtubules that form the neuronal cytoskeleton. Tau mutations have been linked with dementia and Alzheimer’s disease, and accumulation of phosphorylated tau protein (p-tau) has been implicated in neurodegeneration. However, the molecular mechanisms that underlie abnormal tau aggregation have not been elucidated.
“We know that an enzyme called SIRT1 is reduced in the Alzheimer’s disease brain and that this reduction correlates with the accumulation of p-tau. Further, overexpression of SIRT1 protects against neuronal loss in a mouse model of Alzheimer’s disease,” explains senior study author, Dr. Li Gan. “However, how SIRT1 protects against tau-mediated neurodegeneration is not clear.”
SIRT1 is a deacetylase, an enzyme that removes acetyl groups from proteins. Like phosphorylation, acetylation regulates many different cellular functions, including cytoskeleton dynamics. “To determine whether tau is acetylated and whether tau acetylation contributes to tau accumulation, we investigated tau acetylation in neurons, mouse models of tauopathy, and Alzheimer’s disease brains,” says Dr. Gan.
Dr. Gan’s group found that tau acetylation prevents degradation of p-tau, and patients at early and moderate stages of tauopathy exhibited elevated tau acetylation. The researchers went on to show that inhibiting SIRT1 increased levels of acetylated and pathogenic tau while a small molecule inhibitor of p300, an enzyme known to attach acetyl groups to proteins, promoted tau deacetylation and eliminated p-tau associated with pathological conditions.
While the link between tau acetylation and tau phosphorylation is not known, the results provide new insight into tau-mediated neuropathology. “Our findings support the model that the abnormally elevated acetylation at an early stage of the disease could block clearance of p-tau from neurons, leading to its accumulation,” concludes Dr. Gan. “Our observation that p300 diminished tau acetylation and effectively eliminated p-tau supports the idea that interfering with tau acetylation may be a new approach for reducing tau-related pathology.”
1. Li Gan, et al. Acetylation of Tau Inhibits Its Degradation and Contributes to Tauopathy. Neuron, 2010; 67 (6): 953-966 DOI: 10.1016/j.neuron.2010.08.044